Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA

Rank in Stocks #19388
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.26
Last synced: 2026-11-18
Market Cap
$101.72M
Change (1 day)
-0.61%
Change (1 year)
-33.83%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
P/B ratio for Heidelberg Pharma AG (HPHA)
P/B ratio as of November 2026 TTM: -4.86
According to Heidelberg Pharma AG's latest financial reports and stock price, its current price-to-book ratio (TTM) is -4.86. At the end of 2025 the company had a P/B ratio of -12.31.
P/B ratio history for Heidelberg Pharma AG from 2006 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) -4.86 -60.51%
2025 -12.31 -439.71%
2024 3.62 39.03%
2023 2.61 -18.44%
2022 3.20 -87.28%
2021 25.13 108.22%
2020 12.07 215.47%
2019 3.83 23.63%
2018 3.09 192.03%
2017 1.06 -80.11%
2016 5.33 230.82%
2015 1.61 16.78%
2014 1.38 -55.44%
2013 3.10 126.28%
2012 1.37 -101.48%
2011 -92.16 37.63%
2010 -66.96 -412.94%
2009 21.40 168.89%
2008 7.96 203.78%
2007 2.62 -26.99%
2006 3.59 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.5305 -234.33%
US
13.101 -369.48%
US
4.451 -191.55%
AU
4.8339 -199.43%
BE
7.2161 -248.43%
NL

Questions about Heidelberg Pharma AG's P/B ratio

What is Heidelberg Pharma AG's P/B ratio?

Heidelberg Pharma AG's P/B ratio is -4.86, as of Nov 2026.

What was Heidelberg Pharma AG's P/B ratio in 2025?

In 2025, Heidelberg Pharma AG's P/B ratio was -12.31, compared with 3.62 in 2024.

How has Heidelberg Pharma AG's P/B ratio changed since 2020?

From 2020 to 2025, Heidelberg Pharma AG's P/B ratio was highest in 2021 (25.13) and lowest in 2025 (-12.31).

How does Heidelberg Pharma AG's P/B ratio compare with similar companies?

Heidelberg Pharma AG's P/B ratio (-4.86) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 13.10.